Skip to main content

Table 6 Results from ACR analysis: Mean estimate with 80% credible intervals for each pair-wise comparison

From: The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis

Comparison

ACR 20

ACR 50

ACR 70

ACRcont

Ada vs P

4.2 (3.4,5.3)*

5.6 (4.3,7.2)*

7.0 (4.3,10.9)*

0.27 (0.25,0.29)*

Inf vs P

3.5 (2.8,4.4)*

3.4 (2.7,4.4)*

3.7 (2.3,5.5)*

0.24 (0.22,0.27)*

Eta vs P

8.8 (5.5,13.9)*

12.1 (5.7,23.2)*

30.9 (4.2,123.8)*

0.32 (0.28,0.35)*

Gol vs P

3.3 (2.3,4.8)*

4.2 (2.7,6.5)*

6.5 (2.8,13.3)*

0.25 (0.21,0.28)*

Cert vs P

10.6 (8.0,14.1)*

9.5 (6.7,13.5)*

14.3 (6.8,27.0)*

0.32 (0.30,0.35)*

Inf vs Ada

0.8 (0.6,1.1)

0.6 (0.4,0.9)*

0.5 (0.3,1.0)*

-0.03 (-0.06,0.00)*

Eta vs Ada

2.1 (1.2,3.4)*

2.2 (0.96,4.2)

4.4 (0.6,19.0)

0.05 (0.01,0.09)*

Eta vs Inf

2.5 (1.5,4.1)*

3.5 (1.5,6.9)*

8.3 (1.1,37.7)*

0.08 (0.03,0.12)*

Gol vs Ada

0.8 (0.5,1.2)

0.8 (0.4,1.2)

0.9 (0.4,2.2)

-0.02 (-0.06,0.02)

Gol vs Inf

0.9 (0.6,1.5)

1.2 (0.7,2.0)

1.7 (0.7,4.1)

0.01 (-0.04,0.05)

Gol vs Eta

0.4 (0.2,0.7)*

0.3 (0.2,0.8)*

0.2 (0.0,1.8)

-0.07 (-0.12,-0.02)*

Cert vs Ada

2.5 (1.8,3.6)*

1.7 (1.1,2.6)*

2.1 (0.9,4.7)

0.05 (0.02,0.09)*

Cert vs Inf

3.0 (2.1,4.3)*

2.8 (1.8,4.3)*

3.8 (1.7,8.3)*

0.08 (0.05,0.12)*

Cert vs Eta

1.2 (0.7,2.0)

0.8 (0.4,1.8)

0.5 (0.1,3.6)

0.01 (-0.04,0.05)

Cert vs Gol

3.2 (2.0,5.1)*

2.3 (1.3,3.9)*

2.2 (0.8,6.4)

0.08 (0.03,0.12)*

σ

0.2 (0.0,0.4)

0.2 (0.0,0.4)

0.5 (0.0,0.8)

0.03 (0.01,0.04)

  1. Significant results are marked with ∗. Outcome measures are ORs for ACR 20, ACR 50 and ACR 70 and % improvement for ACRcont. Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo, σ=between trial SD.